Il-Yang Dapagliflozin Metformin Extended-Release Tablets 5/1000 mg
Dapagliflozin citric acid 7.35mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
Il-Yang Pharmaceutical Co., Ltd.
MFDS item code 202106877 · Approved 2021.10.12
Improvement of glycemic control in adults with type 2 diabetes mellitus
This medication helps improve blood sugar control in adult patients with type 2 diabetes by using dapagliflozin and metformin together. It is administered as an adjunct to diet and exercise in patients whose blood sugar is not adequately controlled. It can also be used in patients with cardiovascular disease or risk factors; however, it is important to refer to expert guidance while using this medication. This medication effectively improves blood sugar control in type 2 diabetes patients.
The dose of this medicine should be individualized based on the patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended doses of dapagliflozin 10mg and extended-release metformin 2000mg. This medicine is generally administered once daily with the evening meal. The maximum dose of this medicine is dapagliflozin 10mg/extended-release metformin 2000mg once daily, administered as 2 tablets of 5mg/1000mg. Patients with no history of prior antidiabetic drug therapy in whom adequate glycemic control is difficult to achieve with monotherapy: When used as initial therapy in patients with no history of prior antidiabetic drug therapy, the recommended starting dose of this medicine is 1 tablet of 5mg/500mg or 10mg/500mg once daily. Titrate the dose gradually to reduce gastrointestinal adverse reactions to metformin. For patients receiving metformin, the recommended dose of dapagliflozin is 10mg once daily, and the dose of this medicine should provide the patient's current metformin dose or an appropriate dose therapeutically close to it. When switching from immediate-release to extended-release metformin, glycemic control should be closely monitored and dosage adjustments made as appropriate. For patients switching from concomitant dapagliflozin and metformin therapy to this medicine, treatment may be started at their existing doses of dapagliflozin and metformin. When switching from immediate-release to extended-release metformin, glycemic control should be closely monitored and dosage adjustments made as appropriate. When this medicine is used in combination with insulin or an insulin secretagogue such as a sulfonylurea, a lower dose of insulin or the insulin secretagogue may be considered to reduce the risk of hypoglycemia. The safety and efficacy of this medicine have not been specifically evaluated in patients switching to it from other glucose-lowering medicines. Because any change may alter glycemic control, changes in the treatment of patients with type 2 diabetes should be made under careful monitoring. This medicine must be swallowed whole and must never be crushed, cut, or chewed. Occasionally, inactive ingredients of this medicine may be excreted in the stool as a soft, hydrated mass resembling a tablet. Renal impairment No dosage adjustment is necessary in patients with mild renal impairment. For patients with an estimated glomerular filtration rate (eGFR) of 45 mL/min/1.73 m2 or higher and less than 60 mL/min/1.73 m2, without other conditions that may increase the risk of lactic acidosis, the starting dose of metformin hydrochloride, a component of this medicine, is 500mg once daily, and the maximum daily dose is 1000mg. Use of this medicine is not recommended in patients with an eGFR of less than 45 mL/min/1.73m2. If the estimated glomerular filtration rate (eGFR) decreases to less than 45 mL/min/1.73m2, this medicine must be discontinued immediately. Renal function should be assessed every 3~6 months. Older adults Metformin is excreted through the kidneys, and renal function is more likely to be reduced in older adults; therefore, this medicine should be used with caution as age increases (see Precautions for Use, 9. Administration to Older Adults, Patient section).
This medication is used for the treatment of diabetes and helps to control blood sugar levels. However, this medication may rarely cause a dangerous condition called lactic acidosis, so it should not be used in cases of impaired kidney function, severe infection, or dehydration. Additionally, caution is needed when used in combination with insulin or sulfonylurea drugs, as there is a risk of hypoglycemia. Patients with moderate to severe renal impairment, acute illness, severe heart failure, acute myocardial infarction, or hepatic dysfunction should also not take this medication. Patients scheduled for surgery or radiologic contrast studies should discontinue this medication for a certain period, and patients with reduced blood volume or risk of hypotension should use it cautiously. During treatment, genital and urinary tract infections may occur, and immediate treatment is required if symptoms arise. This medication may lower vitamin B12 levels, so regular monitoring of vitamin B12 levels is recommended for long-term use. Excessive alcohol consumption can also increase the risk of side effects of this medication, so it should be avoided. Women who are pregnant or breastfeeding should not use this medication, and elderly patients should take it while regularly monitoring kidney function. In case of overdose, appropriate treatment is necessary, and prompt medical evaluation is critical. This medication does not significantly affect driving or operating machinery but may cause dizziness, so caution is advised. Finally, keep this medication out of the reach of children and store it in its original container to prevent misuse or degradation.
Not everyone experiences these, and they can vary from person to person.
This medication should be stored in a sealed container to keep out air and moisture and should be kept at room temperature between 1 to 30 degrees Celsius. Storing it this way will help maintain the effectiveness of the medication for a longer period.
Deep pink, biconvex, egg-shaped film-coated tablet
30 tablets/bottle
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Dapagliflozin citric acid 7.35mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
Il-Yang Pharmaceutical Co., Ltd.
CombinationDapagliflozin citric acid 14.7mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
HK Inno.N Co., Ltd.
CombinationDapagliflozin citric acid 7.35mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
HK inno.N Co., Ltd.
Dapagliflozin citric acid 14.7mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
Poonglim Pharmaceutical Co., Ltd.
Dapagliflozin citric acid 7.35mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
Punglim Muhak Co., Ltd.
CombinationDapagliflozin citric acid 14.7mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
Korea Prime Pharmaceutical Co., Ltd.
Dapagliflozin citric acid 7.35mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
Korea Prime Pharmaceutical Co., Ltd.
CombinationDapagliflozin citric acid 14.7mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
KS Pharm Co., Ltd.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.